We are analyzing https://link.springer.com/article/10.1186/s13045-015-0224-3.

Title:
ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development | Journal of Hematology & Oncology
Description:
With the advent of new agents targeting CD20, Bruton’s tyrosine kinase, and phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist than ever before. B-cell lymphoma-2 (BCL-2) plays a major role in cellular apoptosis and is a druggable target. Small molecule inhibitors of BCL-2 are in active clinical studies. ABT-199 (venetoclax, RG7601, GDC-0199) has been granted breakthrough designation by FDA for relapsed or refractory CLL with 17p deletion. In this review, we summarized the latest clinical development of ABT-199/venetoclax and other novel agents targeting the BCL-2 proteins.
Website Age:
28 years and 1 months (reg. 1997-05-29).

Matching Content Categories {📚}

Education
Science
Health & Fitness

Content Management System {📝}

What CMS is link.springer.com built with?

Custom-built

No common CMS systems were detected on Link.springer.com, and no known web development framework was identified.

Traffic Estimate {📈}

What is the average monthly size of link.springer.com audience?

🌠 Phenomenal Traffic: 5M - 10M visitors per month

Based on our best estimate, this website will receive around 5,000,019 visitors per month in the current month.
However, some sources were not loaded, we suggest to reload the page to get complete results.

check SE Ranking
check Ahrefs
check Similarweb
check Ubersuggest
check Semrush

How Does Link.springer.com Make Money? {💸}

We're unsure how the site profits.

Websites don't always need to be profitable; some serve as platforms for education or personal expression. Websites can serve multiple purposes. And this might be one of them. Link.springer.com could be secretly minting cash, but we can't detect the process.

Keywords {🔍}

pubmed, abt, google, scholar, article, bcl, patients, cas, central, leukemia, cell, lymphoma, cll, proteins, cancer, phase, study, cells, oncol, chronic, combination, hematol, inhibitors, inhibitor, blood, lymphocytic, family, mcl, clinical, activity, nct, liu, apoptosis, gdc, bclxl, dose, malignancies, acute, vivo, dosing, relapsedrefractory, pts, death, thrombocytopenia, response, med, treatment, role, studies, relapsed,

Topics {✒️}

chronic lymphocytic leukaemia chimeric t-cell receptors diffuse large b-cell adult t-cell leukemia/lymphoma preventing pi3k/akt/mtor activation chimeric antigen receptor-engineered article download pdf apoptosis-inducing factor t-cell immune suppression cd19-negative relapses occurring relapsed cd30-positive lymphomas aggressive myc-driven lymphomas nk cell-mediated immunotherapy anti-cd19 monoclonal antibody small-cell lung cancer chimeric antigen receptor nk cell-specific antibodies anti-apoptotic bcl-2 proteins anti-apoptotic proteins bcl-2 b-cell lymphoma-2 xpo1/crm1-selective inhibitors cml stem/progenitor cells acute myeloid leukemia tyrosine kinase inhibitors chronic lymphocytic leukemia targeted high-affinity inhibitor bcl-xl-dependent resistance bcl-xl levels culminating bcl-2-related protein a1 inhibitory manner tetravalent bispecific tandab nucleo-cytoplasmic transport acute lymphoblastic leukemia b-cell malignancies bcl-2-specific bh3 mimetic dose-limiting severe thrombocytopenia chronic lymphoid leukemia mantle cell lymphoma median progression-free survival privacy choices/manage cookies cd30+ tumor cells anti-apoptotic proteins anti-apoptotic protein furman rr van oers mh high-risk relapsed/refractory small lymphocytic lymphoma henan cancer hospital cell death differ cell death dis

Questions {❓}

BTKi, venetoclax, obinutuzumab: what is the ideal combination?
Role of Bcl-2 family proteins in apoptosis: apoptosomes or mitochondria?

Schema {🗺️}

WebPage:
      mainEntity:
         headline:ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
         description:With the advent of new agents targeting CD20, Bruton’s tyrosine kinase, and phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist than ever before. B-cell lymphoma-2 (BCL-2) plays a major role in cellular apoptosis and is a druggable target. Small molecule inhibitors of BCL-2 are in active clinical studies. ABT-199 (venetoclax, RG7601, GDC-0199) has been granted breakthrough designation by FDA for relapsed or refractory CLL with 17p deletion. In this review, we summarized the latest clinical development of ABT-199/venetoclax and other novel agents targeting the BCL-2 proteins.
         datePublished:2015-11-20T00:00:00Z
         dateModified:2015-11-20T00:00:00Z
         pageStart:1
         pageEnd:8
         license:http://creativecommons.org/publicdomain/zero/1.0/
         sameAs:https://doi.org/10.1186/s13045-015-0224-3
         keywords:
            Follicular Lymphoma
            Mantle Cell Lymphoma
            Overall Response Rate
            Nilotinib
            Bendamustine
            Oncology
            Hematology
            Cancer Research
         image:
            https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13045-015-0224-3/MediaObjects/13045_2015_224_Fig1_HTML.gif
         isPartOf:
            name:Journal of Hematology & Oncology
            issn:
               1756-8722
            volumeNumber:8
            type:
               Periodical
               PublicationVolume
         publisher:
            name:BioMed Central
            logo:
               url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
               type:ImageObject
            type:Organization
         author:
               name:Shundong Cang
               affiliation:
                     name:The Henan Province People’s Hospital
                     address:
                        name:Department of Oncology, The Henan Province People’s Hospital, Zhengzhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Chaitanya Iragavarapu
               affiliation:
                     name:Westchester Medical Center and New York Medical College
                     address:
                        name:Department of Medicine, Westchester Medical Center and New York Medical College, New York, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:John Savooji
               affiliation:
                     name:Westchester Medical Center and New York Medical College
                     address:
                        name:Department of Medicine, Westchester Medical Center and New York Medical College, New York, USA
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Yongping Song
               affiliation:
                     name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University
                     address:
                        name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
                        type:PostalAddress
                     type:Organization
               type:Person
               name:Delong Liu
               affiliation:
                     name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University
                     address:
                        name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
                        type:PostalAddress
                     type:Organization
               email:[email protected]
               type:Person
         isAccessibleForFree:1
         type:ScholarlyArticle
      context:https://schema.org
ScholarlyArticle:
      headline:ABT-199 (venetoclax) and BCL-2 inhibitors in clinical development
      description:With the advent of new agents targeting CD20, Bruton’s tyrosine kinase, and phosphoinositol-3 kinase for chronic lymphoid leukemia (CLL), more treatment options exist than ever before. B-cell lymphoma-2 (BCL-2) plays a major role in cellular apoptosis and is a druggable target. Small molecule inhibitors of BCL-2 are in active clinical studies. ABT-199 (venetoclax, RG7601, GDC-0199) has been granted breakthrough designation by FDA for relapsed or refractory CLL with 17p deletion. In this review, we summarized the latest clinical development of ABT-199/venetoclax and other novel agents targeting the BCL-2 proteins.
      datePublished:2015-11-20T00:00:00Z
      dateModified:2015-11-20T00:00:00Z
      pageStart:1
      pageEnd:8
      license:http://creativecommons.org/publicdomain/zero/1.0/
      sameAs:https://doi.org/10.1186/s13045-015-0224-3
      keywords:
         Follicular Lymphoma
         Mantle Cell Lymphoma
         Overall Response Rate
         Nilotinib
         Bendamustine
         Oncology
         Hematology
         Cancer Research
      image:
         https://media.springernature.com/lw1200/springer-static/image/art%3A10.1186%2Fs13045-015-0224-3/MediaObjects/13045_2015_224_Fig1_HTML.gif
      isPartOf:
         name:Journal of Hematology & Oncology
         issn:
            1756-8722
         volumeNumber:8
         type:
            Periodical
            PublicationVolume
      publisher:
         name:BioMed Central
         logo:
            url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
            type:ImageObject
         type:Organization
      author:
            name:Shundong Cang
            affiliation:
                  name:The Henan Province People’s Hospital
                  address:
                     name:Department of Oncology, The Henan Province People’s Hospital, Zhengzhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Chaitanya Iragavarapu
            affiliation:
                  name:Westchester Medical Center and New York Medical College
                  address:
                     name:Department of Medicine, Westchester Medical Center and New York Medical College, New York, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:John Savooji
            affiliation:
                  name:Westchester Medical Center and New York Medical College
                  address:
                     name:Department of Medicine, Westchester Medical Center and New York Medical College, New York, USA
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Yongping Song
            affiliation:
                  name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University
                  address:
                     name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
                     type:PostalAddress
                  type:Organization
            type:Person
            name:Delong Liu
            affiliation:
                  name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University
                  address:
                     name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
                     type:PostalAddress
                  type:Organization
            email:[email protected]
            type:Person
      isAccessibleForFree:1
["Periodical","PublicationVolume"]:
      name:Journal of Hematology & Oncology
      issn:
         1756-8722
      volumeNumber:8
Organization:
      name:BioMed Central
      logo:
         url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
         type:ImageObject
      name:The Henan Province People’s Hospital
      address:
         name:Department of Oncology, The Henan Province People’s Hospital, Zhengzhou, China
         type:PostalAddress
      name:Westchester Medical Center and New York Medical College
      address:
         name:Department of Medicine, Westchester Medical Center and New York Medical College, New York, USA
         type:PostalAddress
      name:Westchester Medical Center and New York Medical College
      address:
         name:Department of Medicine, Westchester Medical Center and New York Medical College, New York, USA
         type:PostalAddress
      name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University
      address:
         name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
         type:PostalAddress
      name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University
      address:
         name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
         type:PostalAddress
ImageObject:
      url:https://www.springernature.com/app-sn/public/images/logo-springernature.png
Person:
      name:Shundong Cang
      affiliation:
            name:The Henan Province People’s Hospital
            address:
               name:Department of Oncology, The Henan Province People’s Hospital, Zhengzhou, China
               type:PostalAddress
            type:Organization
      name:Chaitanya Iragavarapu
      affiliation:
            name:Westchester Medical Center and New York Medical College
            address:
               name:Department of Medicine, Westchester Medical Center and New York Medical College, New York, USA
               type:PostalAddress
            type:Organization
      name:John Savooji
      affiliation:
            name:Westchester Medical Center and New York Medical College
            address:
               name:Department of Medicine, Westchester Medical Center and New York Medical College, New York, USA
               type:PostalAddress
            type:Organization
      name:Yongping Song
      affiliation:
            name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University
            address:
               name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
               type:PostalAddress
            type:Organization
      name:Delong Liu
      affiliation:
            name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University
            address:
               name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
               type:PostalAddress
            type:Organization
      email:[email protected]
PostalAddress:
      name:Department of Oncology, The Henan Province People’s Hospital, Zhengzhou, China
      name:Department of Medicine, Westchester Medical Center and New York Medical College, New York, USA
      name:Department of Medicine, Westchester Medical Center and New York Medical College, New York, USA
      name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China
      name:Henan Cancer Hospital and the Affiliated Cancer Hospital of Zhengzhou University, Zhengzhou, China

External Links {🔗}(288)

Analytics and Tracking {📊}

Google Tag Manager

Libraries {📚}

Clipboard.js
Prism.js

CDN Services {📦}

Crossref

6.22s.

LINK . SPRINGER . COM {}